2UZU

PKA structures of indazole-pyridine series of AKT inhibitors


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.4 Å
  • R-Value Free: 0.371 
  • R-Value Work: 0.318 

wwPDB Validation 3D Report Full Report


This is version 1.2 of the entry. See complete history

Literature

Syntheses of Potent, Selective, and Orally Bioavailable Indazole-Pyridine Series of Protein Kinase B/Akt Inhibitors with Reduced Hypotension.

Zhu, G.D.Gandhi, V.B.Gong, J.Thomas, S.Woods, K.W.Song, X.Li, T.Diebold, R.B.Luo, Y.Liu, X.Guan, R.Klinghofer, V.Johnson, E.F.Bouska, J.Olson, A.Marsh, K.C.Stoll, V.S.Mamo, M.Polakowski, J.Campbell, T.J.Martin, R.L.Gintant, G.A.Penning, T.D.Li, Q.Rosenberg, S.H.Giranda, V.L.

(2007) J.Med.Chem. 50: 2990

  • DOI: 10.1021/jm0701019
  • Primary Citation of Related Structures:  

  • PubMed Abstract: 
  • Compound 7 was identified as a potent (IC50 = 14 nM), selective, and orally bioavailable (F = 70% in mouse) inhibitor of protein kinase B/Akt. While promising efficacy was observed in vivo, this compound showed effects on depolarization of Purkinje f ...

    Compound 7 was identified as a potent (IC50 = 14 nM), selective, and orally bioavailable (F = 70% in mouse) inhibitor of protein kinase B/Akt. While promising efficacy was observed in vivo, this compound showed effects on depolarization of Purkinje fibers in an in vitro assay and CV hypotension in vivo. Guided by an X-ray structure of 7 bound to protein kinase A, which has 80% homology with Akt in the kinase domain, our efforts have focused on structure-activity relationship (SAR) studies of the phenyl moiety, in an attempt to address the cardiovascular liability and further improve the Akt potency. A novel and efficient synthetic route toward diversely substituted phenyl derivatives of 7 was developed utilizing a copper-mediated aziridine ring-opening reaction as the key step. To improve the selectivity of these Akt inhibitors over other protein kinases, a nitrogen atom was incorporated into selected phenyl analogues of 7 at the C-6 position of the methyl indazole scaffold. These modifications resulted in the discovery of inhibitor 37c with greater potency (IC50 = 0.6 nM vs Akt), selectivity, and improved cardiovascular safety profile. The SARs, pharmacokinetic profile, and CV safety of selected Akt inhibitors will be discussed.


    Organizational Affiliation

    Cancer Research, Preclinical Safety, Structural Biology, Integrative Pharmacology, GPRD, Abbott Laboratories, 100 Abbott Park Road, Abbott Park, Illinois 60064-6101, USA. gui-dong.zhu@abbott.com




Macromolecules

Find similar proteins by: Sequence  |  Structure

Entity ID: 1
MoleculeChainsSequence LengthOrganismDetails
CAMP-DEPENDENT PROTEIN KINASE, ALPHA-CATALYTIC SUBUNIT
E
336Bos taurusMutation(s): 0 
Gene Names: PRKACA
EC: 2.7.11.11
Find proteins for P00517 (Bos taurus)
Go to Gene View: PRKACA
Go to UniProtKB:  P00517
Entity ID: 2
MoleculeChainsSequence LengthOrganismDetails
CAMP-DEPENDENT PROTEIN KINASE INHIBITOR ALPHA
I
20Bos taurusMutation(s): 0 
Gene Names: PKIA
Find proteins for Q3SX13 (Bos taurus)
Go to Gene View: PKIA
Go to UniProtKB:  Q3SX13
Small Molecules
Ligands 1 Unique
IDChainsName / Formula / InChI Key2D Diagram3D Interactions
L20
Query on L20

Download SDF File 
Download CCD File 
E
(2S)-1-(1H-INDOL-3-YL)-3-{[5-(3-METHYL-1H-INDAZOL-5-YL)PYRIDIN-3-YL]OXY}PROPAN-2-AMINE
C24 H23 N5 O
YWTBGJGMTBHQTM-IBGZPJMESA-N
 Ligand Interaction
External Ligand Annotations 
IDBinding Affinity (Sequence Identity %)
L20IC50: 0.16 nM BINDINGMOAD
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.4 Å
  • R-Value Free: 0.371 
  • R-Value Work: 0.318 
  • Space Group: P 21 21 21
Unit Cell:
Length (Å)Angle (°)
a = 72.755α = 90.00
b = 74.748β = 90.00
c = 80.049γ = 90.00
Software Package:
Software NamePurpose
SCALEPACKdata scaling
CNXphasing
HKL-2000data reduction
CNSrefinement

Structure Validation

View Full Validation Report or Ramachandran Plots



Entry History 

Revision History 

  • Version 1.0: 2007-06-05
    Type: Initial release
  • Version 1.1: 2011-05-08
    Type: Version format compliance
  • Version 1.2: 2011-07-13
    Type: Version format compliance